Pfizer Inc. (NYSE:PFE) Holdings Decreased by ARS Wealth Advisors Group LLC

ARS Wealth Advisors Group LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.9% during the first quarter, Holdings Channel.com reports. The firm owned 24,239 shares of the biopharmaceutical company’s stock after selling 728 shares during the period. ARS Wealth Advisors Group LLC’s holdings in Pfizer were worth $614,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of PFE. Norges Bank bought a new stake in shares of Pfizer during the fourth quarter valued at about $2,328,986,000. Charles Schwab Investment Management Inc. raised its stake in shares of Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after purchasing an additional 25,315,159 shares in the last quarter. Starboard Value LP bought a new stake in shares of Pfizer during the fourth quarter valued at about $407,730,000. Raymond James Financial Inc. acquired a new position in Pfizer during the fourth quarter worth about $274,694,000. Finally, Massachusetts Financial Services Co. MA grew its holdings in Pfizer by 7.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after acquiring an additional 5,350,381 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 1.0%

Shares of PFE opened at $23.36 on Friday. The business’s 50-day moving average price is $22.95 and its 200 day moving average price is $25.00. The stock has a market capitalization of $132.81 billion, a P/E ratio of 16.57, a P/E/G ratio of 0.64 and a beta of 0.57. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s revenue was down 7.8% on a year-over-year basis. During the same quarter last year, the business posted $0.82 EPS. Analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.36%. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on PFE shares. UBS Group lifted their target price on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Cantor Fitzgerald started coverage on Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price on the stock. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.